Skip to Content
Merck
  • Pressure-Driven Mitochondrial Transfer Pipeline Generates Mammalian Cells of Desired Genetic Combinations and Fates.

Pressure-Driven Mitochondrial Transfer Pipeline Generates Mammalian Cells of Desired Genetic Combinations and Fates.

Cell reports (2020-12-31)
Alexander N Patananan, Alexander J Sercel, Ting-Hsiang Wu, Fasih M Ahsan, Alejandro Torres, Stephanie A L Kennedy, Amy Vandiver, Amanda J Collier, Artin Mehrabi, Jon Van Lew, Lise Zakin, Noe Rodriguez, Marcos Sixto, Wael Tadros, Adam Lazar, Peter A Sieling, Thang L Nguyen, Emma R Dawson, Daniel Braas, Justin Golovato, Luis Cisneros, Charles Vaske, Kathrin Plath, Shahrooz Rabizadeh, Kayvan R Niazi, Pei-Yu Chiou, Michael A Teitell
ABSTRACT

Generating mammalian cells with desired mitochondrial DNA (mtDNA) sequences is enabling for studies of mitochondria, disease modeling, and potential regenerative therapies. MitoPunch, a high-throughput mitochondrial transfer device, produces cells with specific mtDNA-nuclear DNA (nDNA) combinations by transferring isolated mitochondria from mouse or human cells into primary or immortal mtDNA-deficient (ρ0) cells. Stable isolated mitochondrial recipient (SIMR) cells isolated in restrictive media permanently retain donor mtDNA and reacquire respiration. However, SIMR fibroblasts maintain a ρ0-like cell metabolome and transcriptome despite growth in restrictive media. We reprogrammed non-immortal SIMR fibroblasts into induced pluripotent stem cells (iPSCs) with subsequent differentiation into diverse functional cell types, including mesenchymal stem cells (MSCs), adipocytes, osteoblasts, and chondrocytes. Remarkably, after reprogramming and differentiation, SIMR fibroblasts molecularly and phenotypically resemble unmanipulated control fibroblasts carried through the same protocol. Thus, our MitoPunch "pipeline" enables the production of SIMR cells with unique mtDNA-nDNA combinations for additional studies and applications in multiple cell types.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2′,3′-Dideoxycytidine, ≥98% (HPLC)